Immunosuppressants Overview
Immunosuppressants prevent transplant rejection and control autoimmune diseases by targeting different stages of immune cell activation. Balancing efficacy against infection risk is the central challenge.
## Immune Activation and Drug Targets
T-cell activation involves three signals: antigen recognition (Signal 1), co-stimulation (Signal 2), and cytokine-driven proliferation (Signal 3). Immunosuppressants can target each stage:
- **Signal 1** -- Calcineurin inhibitors block T-cell receptor signaling.
- **Signal 2** -- Belatacept blocks co-stimulation (CD80/86-CD28).
- **Signal 3** -- mTOR inhibitors and antimetabolites block proliferation.
## Calcineurin Inhibitors
**Cyclosporine** and **tacrolimus** bind cyclophilin and FKBP-12 respectively, both forming complexes that inhibit calcineurin. This prevents NFAT dephosphorylation and nuclear translocation, suppressing IL-2 transcription and T-cell activation. Tacrolimus is 50-100x more potent and has largely replaced cyclosporine in modern protocols.
**Monitoring:** Narrow therapeutic index requires trough level monitoring. Tacrolimus target ranges vary by transplant type and time post-transplant (typically 5-15 ng/mL early, 4-8 ng/mL maintenance).
**Toxicity:** Nephrotoxicity (dose-dependent, both acute vasoconstriction and chronic interstitial fibrosis), neurotoxicity (tremor, headache), hyperglycemia (tacrolimus > cyclosporine), hypertension, hyperlipidemia. Cyclosporine additionally causes gingival hyperplasia and hirsutism.
## Antimetabolites
**Mycophenolate mofetil (MMF)** -- Inhibits inosine monophosphate dehydrogenase (IMPDH), blocking de novo purine synthesis. Lymphocytes depend almost exclusively on this pathway (unlike other cells that have salvage pathways), providing relative selectivity. GI side effects (diarrhea, nausea) are dose-limiting. Teratogenic.
**Azathioprine** -- Prodrug converted to 6-mercaptopurine, interfering with purine synthesis and DNA replication. Largely replaced by MMF in transplant but still used in autoimmune diseases (SLE, IBD, myasthenia gravis). Check TPMT/NUDT15 genotype before starting -- deficiency causes severe myelosuppression.
## mTOR Inhibitors
**Sirolimus (rapamycin)** and **everolimus** bind FKBP-12 (same binding protein as tacrolimus) but inhibit mTOR instead of calcineurin. mTOR blockade arrests T-cell proliferation in the G1-to-S phase. Not nephrotoxic (useful when calcineurin inhibitor toxicity occurs) but cause hyperlipidemia, poor wound healing, mouth ulcers, and proteinuria.
## Corticosteroids
Prednisone is a cornerstone of transplant immunosuppression, particularly in induction and acute rejection. Steroid-free or steroid-minimization protocols are increasingly pursued to avoid metabolic complications.
## Biologic Agents
- **Basiliximab** -- Anti-CD25 (IL-2 receptor) monoclonal antibody used for transplant induction.
- **Anti-thymocyte globulin (ATG)** -- Polyclonal antibody causing T-cell depletion. Used for induction in high-risk patients and steroid-resistant rejection.
- **Belatacept** -- Selective co-stimulation blocker (CTLA-4 Ig). Monthly IV infusion alternative to calcineurin inhibitors, avoiding nephrotoxicity.
## Infection Risk Management
All immunosuppressants increase susceptibility to opportunistic infections. Standard prophylaxis includes trimethoprim-sulfamethoxazole (Pneumocystis jirovecii), valganciclovir (CMV in high-risk transplant), and antifungals in high-risk settings. Vaccination should occur before transplant when possible; live vaccines are contraindicated during immunosuppression.
## Key Takeaways
- Tacrolimus + mycophenolate + corticosteroid is the standard triple-therapy regimen for solid organ transplants.
- Therapeutic drug monitoring is mandatory for calcineurin and mTOR inhibitors.
- Nephrotoxicity from calcineurin inhibitors is the leading cause of chronic allograft injury.
- Infection prophylaxis is as important as rejection prevention in transplant pharmacology.